CLDN3 and prostate cancer: Our data show that, in CRPC cells, the loss of CLDN3 expression is associated with an enrichment in epigenetic repressive marks at CLDN3 promoter region, while in the androgen sensitive prostate cancer cells, expressive CLDN3 epigenetic activating marks are present, suggesting that different transcription factors and coregulators are recruited to CLDN3 promoter region in androgen-sensitive and refractory prostate cancer.